DRKS00008037招募中4 期
A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis (DIMAT-MS) - DIMAT-MS
niversitätsklinikum Münster0 个研究点目标入组 75 人开始时间: 2015年5月22日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomized controlled study
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •Healthy subjects:
- •H-1. Written informed consent must be obtained before any assessment is performed.
- •H-2. Male and female subjects aged 18 - 60 years.
- •H-3. No history of multiple sclerosis or clinically isolated syndrome.
- •H-4. No history of other autoimmune diseases, which has been treated systemically with corticosteroids, immunomodulators or immunosuppressive drugs at any time point.
- •Patients with relapsing remitting multiple sclerosis:
- •MS-1. Written informed consent must be obtained before any assessment is performed.
- •MS-2. Male and female subjects aged 18 - 60 years.
- •MS-3. Patients with RRMS, defined by 2010 revised McDonald criteria.
- •MS-4. Patients with an Expanded Disability Status Scale (EDSS) score of 0-6.0.
- •MS-5. Patients with one of the following treatment status: Naïve to disease modifying (DM) treatment (i.e. no DM treatment for at least 1 month), Currently on MS therapy with interferon ß-1 or glatiramer acetate and willing to switch to dimethyl fumarate (Tecfidera®).
- •MS-6. MRI-scan of the brain = 3 months at screening.
排除标准
- •RRMS patients:
- •MS-1. Known hypersensitivity to dimethyl fumarate or any ingredients of Tecfidera® (microcrystalline cellulose; croscarmellose-sodium; talcum; high dispersion, hydrophobic silicon dioxide; magnesiumstearate (Ph. Eur.); triethylcitrate; methacrylic acid-methacrylate copolymer (1:1) (Ph. Eur.); methacrylic acid-ethylacrylate copolymer (1:1)-dispersion 30% (Ph. Eur.), simeticon, sodiumdodecylsulfate, polysorbate 80, gelantine, titanium oxide (E171), brilliant blue (E133), hydrated Iron(III)-oxide hydroxide (E172), shellac, potassium hydroxide.
- •MS-2. A MS-relapse within 30 days prior to screening.
- •MS-3. Known history of active tuberculosis or active tuberculosis determined by a positive QuantiFERON® TB Gold test (i.e. a negative test result has to be provided at screening unless a negative test result exists from the last 3 months prior to screening).
- •MS-4. Moderate to severe impairment of liver function or persisting elevations > 2 x ULN (confirmed by retest) of serum glutamic pyruvic transaminase/ alanine aminotransferase (SGPT/ALT) or serum glutamic oxaloacetic transaminase/aspartate aminotransferase (SGOT/AST), except patients with confirmed Gilbert´s syndrome (Meulengracht´s disease).
- •MS-5. Moderate to severe impairment of renal function, as shown by serum creatinine > 133 µmol/L (or > 1.5 mg/dL).
- •MS-6. Patients with significantly impaired bone marrow function or significant anemia, leukopenia, neutropenia or thrombocytopenia.
- •MS-7. Women of childbearing potential not utilizing highly effective contraception.
- •Both populations:
- •MS/H-1. Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study.
- •MS/H-2. Subjects unlikely to comply with protocol as determined by investigator, e.g., uncooperative attitude, inability to return for follow-up visits (e.g. major physical disability), and known unlikelihood of completing the study.
- •MS/H-3. Clinically relevant cardiovascular, neurological, endocrine, or other major systemic disease making implementation of the protocol or interpretation of the study results difficult or that would put the subject at risk by participating in the study.
- •MS/H-4. Subjects with ulcerative colitis or Crohn´s disease.
- •MS/H-5. Subjects with a congenital or acquired severe immunodeficiency, a history of cancer (except for basal or squamous cell skin lesions which have been surgically excised, with no evidence of metastasis), lymph proliferative disease, or any subject who has received lymphoid irradiation.
- •MS/H-6. Human immunodeficiency virus (HIV) positive, hepatitis B virus positive or hepatitis C virus positive subjects (i.e. a negative test result has to be provided at screening. In the presence of a negative test result from the last 3 months prior to screening, the test has not to be repeated at screening.).
- •MS/H-7. Acute or chronic infection.
- •MS/H-8. History of drug or alcohol abuse.
- •MS/H-9. Use of adrenocorticotrophic hormone (ACTH) or systemic corticosteroids for 4 weeks prior to screening.
- •MS/H-10. Prior or concomitant use of cytokine therapy or intravenous immunoglobulins in the 3 months prior to screening.
- •MS/H-11. Prior use of alemtuzumab or cladribine.
- •MS/H-12. Prior use (within 1 year) of fingolimod (Gilenya®) or natalizumab (Tysabri®).
- •MS/H-13. Prior use (within 2 years) of mitoxantrone, or other immunosuppressant agents such as azathioprine, cyclophosphamide, cyclosporine, methotrexate or mycophenolate mofetil.
- •MS/H-14. Prior trea
研究者
相似试验
进行中（未招募）
1 期
Investigation of the effect of Dimethyl fumarate on T cells in patients with relapsing remitting Multiple SclerosisEUCTR2014-003481-25-DEniversitätsklinikum Münster67
进行中（未招募）
不适用
A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) - Not ApplicableEUCTR2007-003949-32-ATPfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK88
进行中（未招募）
不适用
A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN).ESTUDIO ALEATORIZADO, MULTICÉNTRICO, CON DOS GRUPOS Y DE DOS AÑOS DE DURACIÓN SOBRE EL TRATAMIENTO CON GENOTROPIN (GENOTONORM- MARCA REGISTRADA EN ESPAÑA) EN NIÑOS DE MUY CORTA EDAD NACIDOS PEQUEÑOS PARA SU EDAD GESTACIONAL: CRECIMIENTO Y NEURODESARROLLO TEMPRANOS (EGN). - Not ApplicableShort Stature children born small for Gestational Age (SGA).Niños de talla baja que nacieron pequeños para su edad gestacional (PEG).MedDRA version: 9.1Level: LLTClassification code 10041093Term: Small for gestational ageEUCTR2007-003949-32-ESPfizer, S.A.88
进行中（未招募）
不适用
A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) - Not ApplicableEUCTR2007-003949-32-NLPfizer Ltd. Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK88
进行中（未招募）
1 期
A two-year multi-centre, randomized two arm study of Genotropin treatment in very young children born small for gestational age: Early Growth and Neurodevelopment (EGN) - Not ApplicableShort Stature children born small for Gestational Age (SGA)MedDRA version: 9.1 Level: LLT Classification code 10041093 Term: Small for gestational ageEUCTR2007-003949-32-GBPfizer Limited, Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK43